Disitamab vedotin
A monoclonal antibody used in cancer treatment
| Disitamab vedotin | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Disitamab vedotin is a monoclonal antibody used in the treatment of certain types of cancer. It is an antibody-drug conjugate (ADC) that targets the HER2 receptor, which is overexpressed in some cancer cells. Disitamab vedotin is designed to deliver a cytotoxic agent directly to the cancer cells, thereby minimizing damage to normal cells.
Mechanism of Action[edit | edit source]
Disitamab vedotin works by targeting the HER2 receptor, a protein that is overexpressed in various cancers, including breast cancer and gastric cancer. The drug is an ADC, which means it consists of a monoclonal antibody linked to a cytotoxic agent. The monoclonal antibody part of disitamab vedotin binds to the HER2 receptor on the surface of cancer cells. Once bound, the entire complex is internalized by the cell, where the cytotoxic agent is released, leading to cell death.
Development and Approval[edit | edit source]
Disitamab vedotin was developed by RemeGen, a biotechnology company based in China. It was approved for medical use in China in 2021 for the treatment of HER2-positive gastric cancer. The drug is currently undergoing clinical trials for other types of cancer, including urothelial carcinoma and breast cancer.
Clinical Trials[edit | edit source]
Clinical trials have shown that disitamab vedotin is effective in shrinking tumors in patients with HER2-positive cancers. In particular, it has shown promise in patients who have not responded to other HER2-targeted therapies. Ongoing trials are investigating its efficacy in combination with other cancer treatments.
Side Effects[edit | edit source]
The side effects of disitamab vedotin are similar to those of other ADCs. Common side effects include fatigue, nausea, and peripheral neuropathy. More serious side effects can include neutropenia and liver toxicity. Patients receiving disitamab vedotin are monitored closely for these adverse effects.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
